All the data in this study suggest that RP4 significantly represses CRC cell growth, migration, and metastasis both in vitro and in vivo, thus implying that FMOD is a potential target for CRC, and RP4 is a promising drug candidate for the clinic. The gene discussed is FMOD; the disease is colorectal carcinoma.